StockIQpro
NASDAQ:LENZ

LENZ Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

LENZ Therapeutics, Inc.'s revenue was $19.1M in fiscal 2025. Free cash flow was −$70.0M, −366.7% of revenue, and the diluted share count rose 35.4%.Summary generated from LENZ Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 24, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$19.1M
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross margin97.8%
Operating margin−477.5%
Net margin−430.3%
ROICn/a
Return on equity−33.6%
Debt / equityn/a
Free cash flow−$70.0M
FCF margin−366.7%
Share count change+35.4%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/a019
Operating income−60−106−72−59−91
Net income−71−101−70−50−82
Free cash flow−59−95−60−60−70

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)